CSL (ASX:CSL) share price is now down 12% in 2 weeks

The CSL Ltd (ASX: CSL) share price has fallen 12% in 2 weeks now. This is significant considering the size of the company. We take a look!
The post CSL (ASX:CSL) share price is now down 12% in 2 weeks appeared first on The Motley Fool Australia. –

Red and white arrows showing share price drop

The CSL Ltd (ASX: CSL) share price seems to be stuck in the doldrums over the last couple of weeks. Shares in the biotherapeutics giant have been on the decline since the company announced its half-year results 2 weeks ago.

Interestingly, CSL reported a significant 45% increase in its net profit after tax. So why is the share price falling? As always, the devil is in the details.

Dividends cut in Aussie dollar terms

No, it’s not CSL picking favourites between the United States and Australia. Due to CSL’s operations being heavily focused in the US, most of the company’s financials are shown in US dollar terms. This causes fluctuations when interchanging between multiple currencies.

In this case, CSL declared a dividend increase of 9% to US$1.09 per share. However, the Australian dollar has strengthened by 17% compared to the USD in the last year. That means the Australian equivalent is actually less. In fact, CSL would have had to increase its dividend by more than 17% for it to increase on last year’s payout for Aussies.

Yesterday’s GDP figures indicate that the currency issue could worsen. Australia’s economy is rebounding strongly, backed up by the surprising 3.1% of GDP growth for the last quarter. The CSL share price also tumbled 1% yesterday.

The disappointing dividend for Australian shareholders is likely in focus today as CSL’s shares go ex-dividend. Meaning, if shareholders wanted to collect this dividend, but don’t want to stick around for the next one, today is the last day they had to wait around for.

CSL COVID-19 vaccine is a straggler

While Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) were provisionally approved earlier in the year, the AstraZeneca (LON: AZN) COVID-19 vaccine that CSL is set to manufacturer locally took a bit longer.

Furthermore, as reported by The Australian Financial Review, the AstraZeneca vaccine has lower efficacy than the Pfizer vaccine.

CSL resorted to an agreement for producing the AstraZeneca vaccine. This came after the company abandoned its own development attempts with the University of Queensland. This decision was made after participants gave false positive readings for HIV.

Foggy future weighs on CSL’s share price

Management warned that plasma collections had been impacted due to the challenging environment in its half results. As a result, CSL had experienced additional costs associated with collecting plasma.

Additionally, analysts at Goldman Sachs made the decision to downgrade CSL’s rating to a neutral. Analysts were concerned that management only reaffirmed guidance on the strong profit lift, instead of upgrading. This was interpreted by the analysts as potentially signalling headwinds for the company.

Accounting for today’s move, the CSL share price has now fallen by 16.5% in the last 12 months. 

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post CSL (ASX:CSL) share price is now down 12% in 2 weeks appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!